Parametric Portfolio Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Parametric Portfolio Associates’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-191,619	Closed	-$2.01M	–	3901
2017 Q3	$2.01M	Sell	191,619 -38,982	-17%	-$372K	﹤0.01%	2579
2017 Q2	$2.54M	Sell	230,601 -21,472	-9%	-$216K	﹤0.01%	2347
2017 Q1	$2.44M	Sell	252,073 -2,843	-1%	-$28.4K	﹤0.01%	2309
2016 Q4	$2.65M	Sell	254,916 -9,416	-4%	-$103K	﹤0.01%	2182
2016 Q3	$3.28M	Sell	264,332 -86,931	-25%	-$1.14M	﹤0.01%	1946
2016 Q2	$3.77M	Buy	351,263 +4,206	+1%	+$44.8K	0.01%	1798
2016 Q1	$3.83M	Buy	347,057 +306,265	+751%	+$3.04M	0.01%	1852
2015 Q4	$498K	Buy	+40,792	New	+$636K	﹤0.01%	3255

Other funds holding AVDL

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Parametric Portfolio Associates's AVDL Position: Q4 2017 in Review

Parametric Portfolio Associates sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 191,619 shares — an estimated $2.01M sold.

Parametric Portfolio Associates first reported a position in AVDL in Q4 2015 and held it in 8 quarters. The position peaked at $3.83M in Q1 2016. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

Parametric Portfolio Associates reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Parametric Portfolio Associates sold 191,619 Avadel Pharmaceuticals shares in Q4 2017, an estimated $2.01M.
Parametric Portfolio Associates first reported a position in Avadel Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Parametric Portfolio Associates's Avadel Pharmaceuticals position peaked at $3.83M in Q1 2016.
83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Parametric Portfolio Associates's 13F filing for Q4 2017, filed 14 Feb 2018.